To date, liquid biopsy, using qPCR, has been approved by FDA and EMA for the detection of EGFR mutations in non-small cell lung cancer (NSCLC) and Kras mutations in colorectal cancer (CRC) [184–186]. Here, EGFR is linked to non-small cell lung carcinoma.